Outlook Therapeutics

Historical price data

Outlook Therapeutics is a late-stage biopharma company with a mission to commercialize the first approved ophthalmic bevacizumab, LYTENAVA™, to replace the risky, off-label use of repackaged Avastin® in ophthalmology. The company has achieved its first major regulatory success with marketing authorization in the EU and UK, has commenced launch in Germany and the UK, and has resubmitted its BLA to the FDA for a potential U.S. approval. Its strategy hinges on capturing a significant portion of the large, cost-sensitive anti-VEGF market by offering a lower-cost, approved alternative to existing branded therapies.

Specialized ophthalmic formulation of bevacizumab, a recombinant humanized monoclonal antibody (mAb) that binds and neutralizes VEGF-A, packaged in a preservative-free, single-use vial for intravitreal injection.